Pharmacogenomics of statin response

Current Opinion in Lipidology

Volumn 18, Issue 4, 2007, Pages 409-414

  Mangravite, Lara M ^a   Krauss, Ronald M ^a,b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Cardiovascular disease; LDL cholesterol; Pharmacogenomics statin

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; ADENOSINE MONOPHOSPHATE DEAMINASE; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CARNITINE PALMITOYLTRANSFERASE; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN PHOSPHORYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPOPROTEIN LIPASE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; EXPERIMENTAL MODEL; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOME ANALYSIS; HETEROZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERLIPOPROTEINEMIA TYPE 3; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MUTATIONAL ANALYSIS; MYALGIA; MYOPATHY; NONHUMAN; PHARMACOGENOMICS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; MUSCULAR DISEASES; PHARMACOGENETICS; TREATMENT OUTCOME;

ANIMALIA;

EID: 34447338590     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328235a5a2     Document Type: Review

References (38)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
4. LaRosa JC. Statins and risk of coronary heart disease. JAMA 2000; 283: 2935-2936.
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
6. Takane H, Miyata M, Burioka N, et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006; 51:822-826. This paper addresses short term versus long term effects on lipid lowering response of variation in genes that alter pharmacokinetic statin profiles, rather than using the standard one dose/one time point approach.
7. Christidis DS, Liberopoulos EN, Kakafika AI, et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther 2006; 11:211-221.
8. Maitland-van der Zee AH, Jukema JW, Zwinderman AH, et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol 2006; 61:327-331.
9. Zuccaro P, Mombelli G, Calabresi L, et al. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007; 55:310-317. This paper utilizes a thoughtful approach to categorization of statin mediated myopathic adverse drug events.
10. Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9:81-86.
11. Goodarzi MO, Taylor KD, Scheuner MT, et al. Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts. Pharmacogenomics J 2007; 7:66-73. This is a comprehensive examination of statin mediated lipid response in association with genetic variation across the entire lipoprotein lipase gene, rather than focusing on a single variant previously identified in relation to basal lipid profiles.
12. Marschang P, Sandhofer A, Ritsch A, et al. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006; 260:151-159.
13. Maitland-van der Zee AH, Boerwinkle E, Arnett DK, et al. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J 2007; 153:54-58.
14. Puccetti L, Pasqui AL, Bruni F, et al. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol 2006 [Epub ahead of print].
15. Nagassaki S, Sertorio JT, Metzger IF, et al. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 2006; 41:1044-1049. This is one of the first attempts to characterize pleiotropic effects of statin treatment using intermediate phenotypes rather than clinical CVD related outcomes.
16. Potaczek DP, Undas A, Szczeklik A. Interleukin-6 (IL-6)-174 G/C polymorphism-lack of association with inflammatory and haemostatic variables in patients with coronary heart disease treated with atorvastatin and quinapril. Int J Cardiol 2006; 112:123-124.
17. Potaczek DP, Undas A, Celinska-Lowenhoff M, Szczeklik A. Interleukin-6-174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood Coagul Fibrinolysis 2006; 17:35-38.
18. Roncal C, Orbe J, Belzunce M, et al. The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin. J Thromb Haemost 2006; 4:1798-1803.
19. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16:873-879.
20. Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006; 79:419-426. This paper reports one of the first attempts to characterize pleiotropic effects of statin treatment using intermediate phenotypes rather than clinical CVD related outcomes.
21. Hedman M, Antikainen M, Holmberg C, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006; 61:706-715.
22. Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006; 79:427-439.
23. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80:356-366.
24. Niemi M, Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006; 16:801-808.
25. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006; 373:99-103.
26. Kim KA, Park PW, Lee OJ, et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47:87-93.
27. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153-162. This study represents a novel approach to elucidating genetic predictors of statin induced myopathy by examining the relationship between variants implicated in nonstatin myopathy and ADR cases.
28. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006; 6:360-374. This is a comprehensive review of earlier studies regarding statin pharmacogenomics.
29. Boekholdt SM, Kuivenhoven JA, Hovingh GK, et al. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol 2004; 15:393-398.
30. Simon JA, Lin F, Hulley SB, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 2006; 97:843-850.
31. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16:624-629.
32. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32:403-425.
33. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75:415-421.
34. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14:429-440.
35. Tachibana-Iimori R, Tabara Y, Kusuhara H, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19:375-380.
36. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5:352-358.
37. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006; 1:e97.
38. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78:330-341.